TOKYO – Takeda Pharmaceutical Co. Ltd., of Japan, plans to restructure its research and development operations to focus primarily on the areas of oncology, gastroenterology and central nervous system, as well as vaccines. To accommodate the mission, R&D facilities in Japan and the U.S. will be expanded, while those in other areas of the world face risk of closure, including the U.K.